Estado atual do tratamento dos defeitos do septo atrial / Current status of the treatment of atrial septal defects

A comunicação interatrial tipo ostium secundum (CIA OS) é uma cardiopatia congênita relativamente frequente, que causa repercussão hemodinâmica para o ventrículo direito, com sobrecarga volumétrica e dilatação da câmara. A maioria dos pacientes é assintomática, porém sintomas podem aparecer depois da segunda década de vida. O tratamento eletivo é usualmente realizado próximo ao quinto ano de vida, podendo ser indicado mais precocemente quando houver sintomatologia exuberante. O fechamento transcateter usando uma prótese de duplo disco é bem estabelecido como a primeira escolha de tratamento para a maioria dos pacientes de anatomia favorável. Foi comprovado que o forame oval patente (FOP) está associado à acidente vascular cerebral isquêmico (AVCI) em pacientes com poucos ou nenhum fator de risco de doença cardiovascular. Recentemente, foi demonstrado que a oclusão transcateter do FOP é superior ao tratamento clínico para prevenir recorrências de AVCI nessa população, em um estudo randomizado com acompanhamento clínico de longo prazo. Este manuscrito revisa as atuais indicações, critérios de seleção do paciente e o seguimento clínico dos pacientes com CIA OS e FOP submetidos ao tratamento transcateter

Ostium secundum atrial septal defect (OS-ASD) is a relatively frequent congenital heart defect that causes hemodynamic burden on the right ventricle with volume overload and chamber dilatation. Most patients are asymptomatic, however symptoms can appear after the second decade of life. Elective treatment is usually performed around the fifth year of life, and may be occasionally indicated earlier if there are exuberant symptoms. Transcatheter closure using a double disc device is well established as the first choice of treatment for most patients with suitable anatomy. Patent foramen ovale (PFO) has been shown to be associated with ischemic stroke in patients with no or limited risk factors for cardiovascular disease. It was recently demonstrated in a randomized trial with long-term follow-up that transcatheter closure of PFO is superior to medical treatment for preventing recurrences of stroke in this patient population. This manuscript reviews the current indications, patient selection criteria, and long-term follow-up in patients with OS-ASD and PFO submitted to transcatheter closure

Mid-Term Outcomes after Percutaneous Closure of the Secundum Atrial Septal Defect with the Figulla-Occlutech Device.

OBJECTIVES: To evaluate the mid-term outcomes after percutaneous closure of the secundum atrial septal defects (ASD) using the Figulla-Occlutech device (FOD). BACKGROUND: Transcatheter closure has become the method of choice for most patients with ASD. Although the FOD may have some advantageous characteristics there is a paucity of data on later outcomes after the use of this relatively new device. METHODS: Observational, single arm study including 200 non-consecutive patients who underwent ASD closure between 04/09 and 07/15 in 2 centers. Device performance, deployment technique, and immediate and mid-term outcomes were assessed. RESULTS: Median age and weight were 24 years (4-72) and 58 kg (15-92), respectively. Single defects were observed in 171 patients (median size of 19 mm). The remainder had multiple or multifenestrated defects. Implantation of FOD (median size of 24 mm) was successful in all (99%), but 2 patients (1 with deficient postero-inferior rim; 1 with a large ASD for the size of the child). Embolization with device retrieval occurred in 2 (1%). Median follow-up of 36 months was obtained in 172 patients. Serial echocardiographic assessment showed complete closure in all but 2 patients, in whom an additional small non-significant posterior defect was purposely left untouched. There have been no episodes of late arrhythmias, device embolization, cardiac erosion, endocarditis, thromboembolism, wire fracture, or death. CONCLUSIONS: Transcatheter closure of ASDs in older children, adolescents, and adults using the FOD was highly successful in a wide range of anatomical scenarios with high closure rates and no complications in mid-term follow-up.

Mid-Term Outcomes after Percutaneous Closure of the Secundum AtrialSeptal Defect with the Figulla-Occlutech Device

The secundum atrial septal defect (ASD) is acommon congenital heart defect (CHD), especially inadults. 1 Most of these defects are amenable for transcatheter closure, which became the method of choice to treat most patients due to its safety and efficacy with excellent mid-to-long term outcomes. 2–5 Although cardiac erosions may occur after the use of the Amplatzer Septal Occluder (ASO),6 this complication is very rare. The Figulla-Occlutech device (FOD;Occlutech, Jena, Germany) is relatively new, being anitinol double-disk occluder with a self-centering mechanism provided by a central connecting waist...

Experiência Inicial com o Implante Percutâneo da Válvula Melody® no Brasil / Initial Experience with Percutaneous Implantation of the MelodyTM Valve in Brazil

Introdução: Stress is associated with cardiovascular diseases.O implante percutâneo da válvula pulmonar é uma alternativa para condutos com disfunção. Descrevemos aqui a primeira experiência com o implante da válvula Melody® no Brasil. Métodos: Foram selecionados pacientes com estenose ou insuficiência pulmonar significativa em condutos de 16 a 22 mm. Foram empregadas técnicas padronizadas. Factibilidade, segurança e eficácia desse procedimento foram avaliadas. Resultados: Desde dezembro de 2013, dez pacientes (média de idade e peso de 16,5 anos e 49 kg, respectivamente) foram submetidos ao procedimento com intervalo médio de 11,9 ± 8,6 anos desde a última cirurgia. Insuficiência pulmonar foi indicação para o tratamento em três pacientes, estenose em dois e lesão mista em cinco. A válvula Melody® foi implantada com sucesso em todos os casos. A média da pressão sistólica do ventrículo direito e a relação ventrículo direito/ventrículo esquerdo diminuíram de 49,2 ± 15,9 para 35,8 ± 5,7 mmHg e de 0,55 ± 0,18 para 0,39 ± 0,08 mmHg (p < 0,01 para ambos). Não observamos estenose e nem insuficiência pulmonar residual significativa. Um paciente teve extravasamento contido requerendo um stent coberto e um segundo implante valvular. Todos os pacientes receberam alta do hospital em 72 horas. As válvulas funcionaram adequadamente ...

Background: Transcatheter pulmonary valve implantation is an alternative for dysfunctional conduits. We report the first experience with the MelodyTM valve implantation in Brazil. Methods: Patients with significant pulmonary stenosis or significant pulmonary insufficiency in conduits measuring 16 to 22 mm were enrolled. Standardized techniques were employed. The feasibility, safety and efficacy of this procedure were assessed. Results: From December 2013, ten patients (mean age and weight of 16.5 years and 49 kg, respectively) have undergone the procedure with a mean interval of 11.9 ± 8.6 years since the last surgery. Pulmonary insufficiency was an indication for treatment in three patients, pulmonary stenosis in two, and mixed lesion in five. The MelodyTM valve was successfully implanted in all cases. Mean right ventricular systolic pressure and right ventricle/left ventricle ratio decreased from 49.2 ± 15.9 to 35.8 ± 5.7 mmHg and from 0.55 ± 0.18 to 0.39 ± 0.08 mmHg (p < 0.01 for both). Significant residual pulmonary stenosis or pulmonary insufficiency was not observed. One patient had a contained conduit tear requiring a covered stent and a second valve implantation. All patients were discharged within 72 hours. The valves were properly functioning in a mean follow-up of 4.1 ± 2.2 months with no complications. Conclusions: Transcatheter MelodyTM valve implantation was feasible, safe and effective ...

Oclusão percutânea de defeitos cardíacos congênitos e estruturais com Amplatzer Duct oOccluder II TM / Percutaneous closure of congenital and structural heart defects with the Amplatzer Duct Occluder II TM

INTRODUÇÃO: Uma nova geração de próteses Amplatzer com menor perfil e maior flexibilidade foi desenvolvida recentemente para o tratamento percutâneo da persistência do canal arterial (PCA). Neste artigo é relatado o uso desse novo dispositivo, Amplatzer Duct Occludder IITM (ADO II), para o tratamento tanto de PCA como de outros defeitos congênitos e estruturais, avaliando sua eficácia e segurança. Métodos: Estudo longitudinal observacional de um coorte de pacientes portadores de cardiopatias congênitas e estruturais tratados com ADO II entre outubro de 2009 e agosto de 2011. Pacientes com menos de 5 kg e canais > 5,5 mm e/ou do tipo B foram excluídos do estudo. A prótese foi implantada por vias anterógrada ou retrógrada. A cintura foi cerca de 2 mm maior que o defeito e o comprimento da prótese foi de 4 mm para lesões mais curtas ( até 6-8 mm). Resultados: Foram incluídos no estudo 28 pacientes, com mediana de idade e de peso de 2 anos e 11,7 kg, respectivamente, dos quais 23 eram portadores de PCA com diâmetro mínimo de 2,3 +- 0,8 mm. Os demais apresentavam...

BACKGROUND: A new generation of Amplatzer devices with lower profile and greater flexibility has been recently developed for percutaneous occlusion of the patent ductus arteriosus (PDA). In this paper, the use of this new device, the Amplatzer Duct Occludder II TM (ADO II) for percutaneous closure of the PDA as well as for the treatment of other congenital and structural heart defects is reported, assessing its safety and efficacy. METHODS: Longitudinal and observational study of a cohort of patients with congenital and structural heart defects treated with ADO II between October 2009 and August 2011. Patients weighing less than 5 kg and PDAs > 5.5 mm and/or type B were excluded. The device was implanted using the antegrade or retrograde approach. The waist was 2 mm larger than the defect and the length of the prosthesis was 4 mm for shorter lesions (less than 6-8 mm). RESULTS: Twenty-eight patients with a median age and weight of 2 years and 11.7 kg, respectively, were included. Twenty-three had a PDA with a mean minimal diameter of 2.3 + 0.8 mm. The remainder had muscular ventricular septal defect (1), pulmonary arteriovenous fistula (1), ruptured aneurysm of the sinus of Valsalva (1), and univentricular heart in the early postoperative period of bidirectional cavopulmonary anastomosis with residual antegrade pulmonary flow (2). The device was successfully implanted in all patients, except for an infant weighing 8 kg with a long, tortuous and oblique PDA with a diameter of 2.8 mm and a shallow ampulla. There was total occlusion of the defects in all patients. One patient with univentricular heart and right isomerism died due to complications not related to the procedure. CONCLUSIONS: ADO II proved to be a flexible, safe and effective device for the percutaneous treatment of infants, children and selected adults with PDA and other congenital and structural heart defects. Its use may have limitations for some anatomical PDA configurations in smaller infants.

Experiência inicial no fechamento percutâneo da comunicação interatrial tipo ostium secundum com a prótese figulla / Initial experience in the percutaneous occlusion of ostium secundum atrial septal defect with the Figulla device

INTRODUÇÃO: O tratamento percutâneo da comunicação interatrial tipo ostium secundum é a modalidade terapêutica de escolha em mais de 80 por cento dos casos. Várias próteses encontram-se disponíveis pra tal finalidade. Relatamos nossa experiência com a oclusão percutânea da comunicação interatrial com a prótese Figulla (Occlutech, Praga, República Tcheca), avaliando a segurança e a eficácia do método. Método: De abril de 2008 a março de 2010, foram realizados 25 procedimentos em dois centros de referência em 25 pacientes não-consecutivos (mediana de idade de 22 anos e de peso de 60 kg) sob anestesia geral e monitoração pela ecocardiografia transesofagica. Do total de comunicações interatriais, 23 eram únicas, com diâmetro...

BACKGROUND: Percutaneous treatment of ostium secundum atrial septal defect is the preferred therapy in over 80% of cases. Several devices are available for this purpose. We report our experience with the percutaneous closure of atrial septal defect with the Figulla device (Occlutech, Prague, Czech Republic) assessing the safety and efficacy of the procedure. METHOD: From April 2008 to March 2010, 25 procedures were performed in 2 reference centers in 25 non-consecutive patients (median age 22 years and median weight 60 kg) under general anesthesia and transesophageal echocardiographic monitoring. Atrial septal defects were single in 23 cases and multiple in 2 cases and had a mean diameter of 17.5 ± 9.4 mm. In one patient it was necessary to use two devices in two distant atrial septal defects. The mean diameter of the devices was 20.8 ± 7.4 mm and they were implanted through 9-14 F long sheaths in the femoral vein. RESULTS: Successful implantation was observed in all cases. In one case, there was embolization immediately after device release. The device was retrieved from the descending aorta followed by implantation of a new device. The mean follow-up was 12 months and the occlusion rate was 100%. There were no late complications. CONCLUSION: In this initial experience, percutaneous occlusion of the atrial septal defect with the Figulla device was easy to perform, safe and highly effective.

Experiência multicêntrica na América do Sul no fechamento perventricular da comunicação interventricular muscular congênita / Perventriculat closure of congenital muscular ventricular septal defect: multicenter experience in South America

Fundamentos: O fechamento perventricular das comunicações interventriculares (CIVs) musculares tornou-se uma altenativa terapêutica atraente em pequenos lactentes com grandes defeitos. Entretanto, a reprodutibilidade desse métodos em vários centros mundiais ainda é uma questão em aberto. Método: Relatamos uma experiência multicêntrica na América do Sul com tal abordagem. No período de julho de 2007 a maio de 2009, nove pacientes não consecutivos (idade e peso médios de 6 meses e 5,5kg, respectivamente) foram submetidos a procedimento no centro cirúgico, sob monitoração da ecocardiográfia transesofágica, utilizando-se dispositivos Amplatzer. Todos os pacientes, com exceção de um, apresentavam insuficiência cardíaca e graus variados de hipertensão pulmonar. Quatro pacientes...

Background: Perventricular closure of muscular ventricular septal defects (VSD) has become an attractive treatment modality for infants. However, its reproducibility worldwide remains to be seen. Methods: We report a multicenter experience in South America. From July, 2007 to May, 2009, nine non-consecutive patients (median age and weight were 6 months and 5.5 kg, respectively) underwent the procedure in the operating room under transesophageal echocardiographic guidance using Amplatzer devices. All patients but one were in congestive heart failure and had pulmonary arterial hypertension. Four patients had coarctation of the aorta and one was submitted to pulmonary artery banding at 6 months of life, which were all repaired at the same session. Eight patients had single defects (six mid-muscular, two apical) measuring 10.3 ± 3.7 mm and one patient had multiple apical defects that required two devices. Results: Ten devices were implanted successfully (median size: 12 mm), and two had to be sutured to the right ventricular wall with a surgical suture. One patient...

Percutaneous closure of Blalock-Taussig shunts using Gianturco coils.

Permeability of a Blalock-Taussig shunt can increase the risk of endocarditis and ventricular overload. Percutaneous embolization of these shunts gives variable results. We report our experience in 10 patients with percutaneous closure of modified Blalock-Taussig shunts using retrograde arterial embolization with Gianturco coils. The patients' median age was 2.8 years, and their median weight was 12 kg. Most patients had minor stenosis of the distal portion of the anastomosis. In all cases, complete closure of the shunt was achieved without complications using a median of one coil per patient. The technique was feasible, safe, effective, and inexpensive.

Cierre percutáneo de la fístula de Blalock-Taussig con espirales de Gianturco / Percutaneous closure of blalock–taussig shunts using gianturco coils

La permeabilidad de una fístula de Blalock-Taussig incrementa el riesgo de endocarditis y sobrecarga ventricular. Los resultados de la embolización percutánea de estos cortocircuitos son variables. Presentamos la experiencia en el cierre percutáneo de la fístula de Blalock-Taussig modificada, utilizando la embolización arterial retrógrada con espirales de Gianturco, en 10 pacientes. Las medianas de edad y peso fueron 2,8 años y 12 kg, respectivamente. La mayoría presentaba una zona de disminución del diámetro en el extremo distal de la conexión. En todos se consiguió un cierre completo del cortocircuito, con una mediana de 1 dispositivo por paciente, y no se registraron complicaciones. La técnica es factible, segura, efectiva y económica (AU)

Permeability of a Blalock-Taussig shunt can increase the risk of endocarditis and ventricular overload. Percutaneous embolization of these shunts gives variable results. We report our experience in 10 patients with percutaneous closure of modified Blalock-Taussig shunts using retrograde arterial embolization with Gianturco coils. The patients' median age was 2.8 years, and their median weight was 12 kg. Most patients had minor stenosis of the distal portion of the anastomosis. In all cases, complete closure of the shunt was achieved without complications using a median of one coil per patient. The technique was feasible, safe, effective, and inexpensive (AU)

Percutaneous Closure of Blalock-Taussig Shunts Using Gianturco Coils

Permeability of a Blalock-Taussig shunt can increase the risk of endocarditis and ventricular overload. Percutaneous embolization of these shunts gives variable results. We report our experience in 10 patients with percutaneous closure of modified Blalock-Taussig shunts using retrograde arterial embolization with Gianturco coils. The patients’ median age was 2.8 years, and their median weight was 12 kg. Most patients had minor stenosis of the distal portion of the anastomosis. In all cases, complete closure of the shunt was achieved without complications using a median of one coil per patient. The technique was feasible, safe, effective, and inexpensive.

Fechamento percutâneo da Comunicação Interventricular muscular congênita / Percutaneous closure of congenital muscular ventricular septal defects

tratamento percutaneo da comunicação interventricular (CIV)congênita vem sendo realizado com bons resultados nos últimos 10 anos. Relatamos nossa experiência com a oclusão percutânea da CIV muscular congênita com próteses Amplatzer avaliando exequibilidade, segurança e eficâcia do método: Método: No período de setembro de 2002 a dezembro de 2007, foram realizados 9 procedimentos em múltiplos centros em 8 pacientes não-concecutivos (mediana de idade de 6 anos e de peso de 26 kg), sob anestesia geral e monitoração pela ecocardiografia transesofágica. Todas as CIVs eram únicas (7 na região trabecular média e 1 na porção anterior) e tinham diâmetro médio de 6,0 mais ou menos 2,1 mm. Houve embolização imediata de um dispositivo com resgate percutâneo. O procedimento foi repetido com sucesso após um ano. Todos os casos restantes foram realizados com sucesso, som complicações maiores. O índice de oclusão foi de 100 por cento no seguimento. Conclusão: Nessa pequena série de pacientes, a oclusão percutânea da CIV muscular congênita única com próteses Amplatzer foi um procedimento de fácil execução, seguro e altamente efizaz.

Background: Percutaneous treatment of muscular ventricular septal defects (VSD) has been performed with good results in the last 10 years. We report our experience with the percutaneous closure of congenital muscular VSDs with Amplatzer devices assessing the feasibility, safety and efficacy of the procedure. Methods: From 9/2002 to 12/ 2007, 9 procedures were performed in multiple centers in 8 non-consecutive patients (median age: 6 years; median weight: 26 kg) under general anesthesia and transesophageal echocardiographic monitoring. All VSDs were single (7 in the trabecular region and 1 anterior) and had a mean diameter of 6.0 ± 2.1 mm. There was one device embolization with immediate percutaneous device retrieval. This procedure was successfully repeated after year. The other cases were completed successfully without major complications. The rate of complete closure was 100% at follow-up. Conclusion: In this small series of patients, percutaneous closure of congenital single muscular VSD was relatively easy to perform, safe and highly effective.

Percutaneous closure of postoperative and post-traumatic ventricular septal defects.

Although uncommon, significant postoperative residual leaks may occur after repair of any type of ventricular septal defect (VSD). Post-traumatic VSDs are even rarer, but can be occasionally seen after penetrating or blunt chest trauma. When these defects are associated with significant left-to-right shunting (Qp/Qs > 1.5) with persistent left ventricular volume overload, intervention is generally recommended. Surgical treatment requires cardiopulmonary bypass with its attendant morbidity, increased hospital stay and possible long-term neurological impairment. With the evolving experience of transcatheter closure of postinfarction and native perimembranous and muscular VSDs, this less invasive method became an attractive alternative to manage these postoperative and post-traumatic defects. In this paper, we report on 3 patients with such residual leaks after repair of a perimembranous defect, which was closed using a perimembranous Amplatzer VSD occluded after a failed attempt using a NitOcclud coil. One patient had a mid-muscular post-traumatic defect after a penetrating chest wound, and another patient had a residual leak after a patch repair of a large post-traumatic muscular defect with outlet extension after a blunt chest trauma. Both defects were closed using muscular Amplatzer VSD occluders. All procedures were uncomplicated, and there were no technical difficulties with device implantation. All 3 patients' defects were completely closed at follow up. Percutaneous closure of traumatic and residual postoperative VSDs appears to be safe and effective. A larger number of patients and longer follow-up period are needed before the widespread use of this technique can be recommended.

Percutaneous closure of postoperative and post-traumatic ventricular septal deffects

Although uncommon, significant postoperative residual leaks may occur after repair of any type of a ventricular septal deffect (VSD). Post-traumatics VSDs are even rarer, but can be occasionally seen after penetrating or blunt chest trauma. When these defects are associated with significant left-to-rigth shunting (Qp/Qs > 1.5) with persistent left ventricular volume overload, intervention is generally recomended. Surgical treatment requires cardiopulmonary bypass with its attendent morbidity, increased hospital stay and possible long-term neurological impairment. With the envolving experience of transcatheter closure of postinfarction and native perimembranous and muscular VSDs, this less invasive method became an attractive alternative to manage these postoperative and post-traumatic deffects...

New transcatheter techniques for creation or enlargement of atrial septal defects in infants with complex congenital heart disease.

OBJECTIVES: To describe a series of 8 consecutive infants (5 with transposition of the great arteries [TGA] and 3 with hypoplastic left heart syndrome [HLHS]) who underwent nonconventional septostomy techniques. BACKGROUND: For some complex congenital heart defects, an unrestrictive atrial septal defect (ASD) is essential to achieve an adequate cardiac output and/or systemic saturation. In some scenarios, the use of conventional septostomy techniques may be technically difficult, hazardous, and/or ineffective. METHODS: Use of transhepatic approach, cutting balloons, and radiofrequency perforation with stenting of the atrial septum. RESULTS: The size of the ASD and the oxygen saturation increased in all patients with no major complications. In those with TGA, the ASDs were considered to be of good size at the arterial switch operation. Two of the 3 patients with hybrid palliation for HLHS have developed some degree of obstruction within the interatrial stent over 2-3 months. At surgery, the stents were found to be secured within the septum with one showing significant fibrous ingrowth after uneventful removal. The other had some nonobstructive ingrowth. CONCLUSIONS: Creation or enlargement of ASDs in infants using new nonconventional transcatheter techniques is feasible, safe, and effective, at least in the short-to-mid-term follow-up. Infants with TGA seem to benefit the most because the procedure results in satisfactory clinical stability for subsequent early surgical intervention. In infants with HLHS palliated by a hybrid approach, stent implantation to the atrial septum seems to buy enough time to bring them to the phase II safely despite progressive in-stent obstruction.

Transhepatic access for atrioseptostomy in a neonate.

We report a case in which a neonate with complete transposition of the great arteries was submitted to an atrial septostomy through transhepatic access due to congenital interruption of the inferior vena cava. The technical aspects of the procedure are discussed.

[Right patent ductus arteriosus with an ipsilateral aortic arch: percutaneous closure with amplatzer devices]. / Conducto arterioso persistente a la derecha con arco aórtico ipsolateral: cierre percutáneo con dispositivos Amplatzer.

The association of a right aortic arch with an ipsilateral patent ductus arteriosus is rare, especially when there are no other intracardiac anomalies. We report three female patients aged 26, 35 and 9 years with this combination in whom previous attempts at surgical closure by thoracotomy and sternotomy were unsuccessful and who subsequently underwent successful percutaneous closure of the defects using Amplatzer devices. In two patients, although angiography demonstrated the presence of type-A patent ductus arteriosus, it was not possible to determine the minimum diameter accurately and it was necessary to measure it using a sizing balloon. An Amplatzer duct occluder was used in two patients and an Amplatzer muscular ventricular septal defect occluder, in the other. In all patients, full closure was confirmed in the catheterization laboratory and the patients were discharged on the same day with no complications. Percutaneous closure of a right patent ductus arteriosus associated with a right aortic arch is feasible, safe and effective.

Conducto arterioso persistente a la derecha con arco aórtico ipsolateral: cierre percutáneo con dispositivos Amplatzer / Right patent ductus arteriosus with an ipsilateral aortic arch: percutaneous closure with amplatzer devices

La asociación de arco aórtico a la derecha con persistencia del conducto arterioso ipsolateral es rara, principalmente cuando no hay otras anomalías intracardiacas asociadas. Comunicamos los casos de 3 pacientes del sexo femenino de 26, 35 y 9 años con esta enfermedad e intentos previos infructuosos de cierre quirúrgico a través de toracotomía y esternotomía, a quienes se realizó cierre percutáneo del defecto con dispositivos tipo Amplatzer con éxito. En 2 pacientes, aunque las angiografías documentaron la presencia de persistencia del conducto arterioso tipo A, no se pudo definir bien el diámetro mínimo y fue necesario determinarlo con el balón medidor. Se implantaron Amplatzer Duct Occluder en 2 pacientes y Amplatzer para comunicación interventricular muscular en el otro. En todos se corroboró el cierre completo del defecto en la sala de hemodinámica y fueron dados de alta sin complicaciones. El cierre percutáneo del conducto derecho en presencia de arco aórtico a la derecha es factible, seguro y efectivo

The association of a right aortic arch with an ipsilateral patent ductus arteriosus is rare, especially when there are no other intracardiac anomalies. We report three female patients aged 26, 35 and 9 years with this combination in whom previous attempts at surgical closure by thoracotomy and sternotomy were unsuccessful and who subsequently underwent successful percutaneous closure of the defects using Amplatzer devices. In two patients, although angiography demonstrated the presence of type-A patent ductus arteriosus, it was not possible to determine the minimum diameter accurately and it was necessary to measure it using a sizing balloon. An Amplatzer duct occluder was used in two patients and an Amplatzer muscular ventricular septal defect occluder, in the other. In all patients, full closure was confirmed in the catheterization laboratory and the patients were discharged on the same day with no complications. Percutaneous closure of a right patent ductus arteriosus associated with a right aortic arch is feasible, safe and effective

Conducto arterioso persistente a la derecha con arco aórtico ipsolateral: cierre percutáneo con dispositivos Amplatzer / Right Patent Ductus Arteriosus With an Ipsilateral Aortic Arch: Percutaneous Closure With Amplatzer Devices

The association of a right aortic arch with an ipsilateralpatent ductus arteriosus is rare, especially when there are no other intracardiac anomalies. We report three female patients aged 26, 35 and 9 years with this combination in whom previous attempts at surgical closure by thoracotomy and sternotomy were unsuccessful and who subsequently underwent successful percutaneous closure of the defects using Amplatzer devices. In two patients, although angiography demonstrated the presence of type-A patent ductus arteriosus, it was not possible to determine the minimum diameter accurately and it was necessary to measure it using a sizing balloon. An Amplatzer duct occluder was used in two patients and an Amplatzer muscular ventricular septal defect occluder, in the other. In all patients, full closure was confirmed in the catheterization laboratory and the patients were discharged on the same day with no complications. Percutaneous closure of a right patent ductus arteriosus associated with a right aortic arch is feasible, safe and effective.